Printer Friendly

Sun Pharma Gets USFDA Approval for Generic Fosamax (R) Tablets.

MUMBAI, India, September 12 /PRNewswire/ -- Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE:SUNPHARMA, BSE: 524715) announced that USFDA has granted final approval for the Company's Abbreviated New Drug Application (ANDA) for generic Fosamax (R), alendronate sodium tablets.

Alendronate sodium tablets are indicated for the treatment and prevention of osteoporosis in post menopausal women, to increase bone mass in men with osteoporosis, in the treatment of glucocorticoid induced osteoporosis, and Paget's disease of the bone in men and women.

These generic versions of alendronate sodium tablets 5 mg (base), 10 mg (base), 35 mg (base) and 70 mg (base) are bio-equivalent to Fosamax (R) tablets distributed by Merck & Co.

These strengths of Fosamax (R) tablets have annual sales of approximately USD 560 million in the US.

These products will reach market shortly.

Fosamax (R) is a registered trademark of Merck & Co.

About Sun Pharmaceutical Industries Ltd.

Established in 1983, listed since 1994 and headquartered in India, Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE:SUNPHARMA, BSE: 524715) is an international, integrated, speciality pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India, US and several other markets across the world. In India, the company is a leader in niche therapy areas of psychiatry, neurology, cardiology, diabetology, gastroenterology, and orthopedics. The company has strong skills in product development, process chemistry, and manufacturing of complex API, as well as dosage forms. More information about the company can be found at http://www.sunpharma.com.

 Uday Baldota,

 Tel: +91-22-6645-5645, Xtn 605,
 Tel Direct: +91-22-66455605,
 Mobile: +91-98670-10529,
 E-mail: uday.baldota@sunpharma.com;

 Mira Desai,

 Tel: +91-22-6645-5645, Xtn 606,
 Tel Direct: +91-22-66455606,
 Mobile: +91-98219-23797,
 E-mail: mira.desai@sunpharma.com



Uday Baldota, Tel: +91-22-6645-5645, Xtn 605, Tel Direct: +91-22-66455605, Mobile: +91-98670-10529, E-mail: uday.baldota@sunpharma.com; Mira Desai, Tel: +91-22-6645-5645, Xtn 606, Tel Direct: +91-22-66455606, Mobile: +91-98219-23797, E-mail: mira.desai@sunpharma.com
COPYRIGHT 2008 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2008 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire Europe
Date:Sep 12, 2008
Words:323
Previous Article:Endeavour Announces Discovery at Noatun C in Norway.
Next Article:MassMutual Appoints Rod Dillman President of MassMutual International.
Topics:


Related Articles
Sun Pharma Gets USFDA Approval for Generic Depakote (R) Delayed Release Tablets.
Sun Pharma Continues Strong Performance.
Sun Pharma Receives USFDA Approvals for 4 Generic Products.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters